Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

Cancer

Volumn 92, Issue 1, 2001, Pages 54-60

  Yang, Qifeng ^a,b   Sakurai, Takeo ^a   Mori, Ichiro ^a   Yoshimura, Goro ^a   Nakamura, Misa ^a   Nakamura, Yasushi ^a   Suzuma, Takaomi ^a   Tamaki, Takeshi ^a   Umemura, Teiji ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b SHANDONG UNIVERSITY   (China)

Author keywords

BRCA1; Immunohistochemistry; Prognosis; Sporadic breast carcinoma

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; JAPAN; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035397553     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8     Document Type: Article

References (38)

1. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
2. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome
3. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
4. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors
5. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases
6. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
7. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers
8. Methylation of the BRCA1 gene in sporadic breast cancer
9. BRCA1 protein products. Functional motifs
10. Transcriptional activation by BRCA1
11. Evidence for a transcriptional activation function of BRCA1 C-terminal region
12. BRCA1 regulates p53-dependent gene expression
13. BRCA1 physically associates with p53 and stimulates its transcriptional activity
14. Association of BRCA1 with Rad51 in mitotic and meiotic cells
15. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
16. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma
17. Thymidine phosphorylase expression in invasive breast carcinoma: Correlations with in vitro chemosensitivity to 5-fluorouracil
18. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
19. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
20. Localization of human BRCA1 and its loss on high-grade, non-inherited breast carcinomas
21. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors
22. Tumor-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer
23. Expression of BRCA1 and BRCA2 in normal and neoplastic cells
24. Inhibition of BRCA1 expression by benzo-[a]pyrene and its diolepoxide
25. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
26. Germ line mutation at BRCA1 affects the histopathologic grade in hereditary breast cancer
27. Tumor biological features of BRCA1-induced breast and ovarian cancer
28. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
29. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes
30. BRCA1-p53 relationship in hereditary breast cancer
31. Drug-target interactions: Only the first step in the commitment to a programmed cell death?
32. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthemia
33. Apoptosis. Biochemical events and relevance to enhancer chemotherapy
34. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
35. Bcl-2: Prevention of apoptosis and a mechanism of drug resistance
36. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines